Condition: Lung Diseases, Interstitial · Pulmonary Alveolar Proteinosis · Pulmonary Eosinophilia · Sponsor: Matthias Griese
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes
This description comes directly from the study's public registry record.
Matthias Griese, Prof. · +49/89/440057871 · Matthias.Griese@med.uni-muenchen.de
Katarzyna Michel, Dr. med. · +49/89/440057878 · Katarzyna.Michel@med.uni-muenchen.de
Always discuss trial participation with your own doctor first.
| Medizinische Hochschule Hannover | Hanover, Lower Saxony, Germany | Recruiting |
| Hacettepe University, Medical Faculty | Ankara, Sihhiye, Turkey (Türkiye) | Recruiting |
| University of Edinburgh | Edinburgh, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02852928